<DOC>
	<DOCNO>NCT01770080</DOCNO>
	<brief_summary>Efficacy safety Euminz® ( 10 % ethanolic solution peppermint oil topical use ) compare placebo patient episodic tension-type headache ( ETTH ) . Prospective , double-blind , placebo-controlled , phase IV clinical trial ; Parallel-groups design ; Randomisation 1:1 ; First attack per patient evaluate primary objective , follow attack study duration observe document . Study duration per patient : 10 week</brief_summary>
	<brief_title>Efficacy Euminz® Tension-Type Headache</brief_title>
	<detailed_description>To demonstrate efficacy Euminz® reduce intensity headache symptom experience patient episodic tension-type headache . The two primary objective test hierarchically ( a-priory order ) avoid alpha-adjustment : First primary objective first headache episode `` pain-free '' ( 0 1 ) 2 hour measure six-step verbal pain rating scale ( VPRS ) . Acute treatment ( 3 5 time topical use Euminz® ) start immediately assessment baseline pain intensity least moderate pain ( 3 VPRS ) . Second primary objective first headache episode decrease intensity pain measure visual analogue scale ( VAS ) . The difference measure point 0 ( first application Euminz® ) VAS comparison 15 , 30 , 45 , 60 , 90 120 minute start treatment show area curve represent pain intensity difference ( PID ) .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Tension-Type Headache</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Peppermint oil</mesh_term>
	<criteria>Male female patient 18 year onwards History ETTH least one year . The number day headache ≥2 per month Onset TTH 65 year age At least 10 previous headache attack fulfil follow four inclusion criterion : Patients headache attack last 30 minute 7 day At least two follow pain characteristic present : Pressing tightening ( nonpulsating ) quality Intensity pain : moderate = unable ignore ( pain may inhibit , prohibit activity ) Bilateral location No aggravation walk stair similar routine physical activity Headache accompany nausea vomiting ( anorexia may occur ) Headache accompany combination follow symptom : photophobia phonophobia ( one may present ) 3 month retrospective history Willingness ability keep patient 's diary comply procedure study Written inform consent Headaches TTH : ( e.g . migraine , cluster headache , hypertension headache , drugrelated headache , analgesicinduced headache , posttraumatic headache ; associate migraine attack permit well recognize patient frequency precede year exceed one per month ) Presence oromandibular dysfunction History facial cranial surgery Use prophylactic drug headache within one month prior enrolment Use drug acute TTH treatment ≥ 10 day headache per month Anticipated problem adhere selfobservation procedure ( e.g . work ) Abuse alcohol , narcotic drug Serious illness within last 3 month ( e.g . myocardial infarction , cardiac insufficiency NYHA III IV , low blood pressure , cerebral insult , diabetes mellitus , neuropathy , change skin neoplasms head ) Epilepsy Intake antipsychotic , antidepressant antiepileptic medication previous month Intake longacting nonsteroidal antiinflammatory drug within last month Planned start new pharmacological nonpharmacological therapy Any significant skin condition affect face neck Known hypersensitivity towards peppermint oil Previous use Euminz® essential oil solution headache last three month Participation another clinical trial within last month Accommodation institution judicial official request</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>